FIMECS Presents at the Protein Degradation in Focus

News release Download PDF

Kanagawa, Japan, 17th May 2024 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the results of its research on targeted protein degraders based on its platform technology, RaPPIDSTM, will be presented at the Protein Degradation in Focus (19-22 May 2024 in University of Dundee, UK) which is a Symposium organized by Professor Alessio Ciulli to bring close to 300 delegate scientists together to mark the opening of new Centre for Targeted Protein Degradation (CeTPD) at Dundee. Not only presenter but also participants are a limited people who have been passed screening by the organizer and Kanae Gamo, Ph.D., CSO of FIMECS has been selected as a presenter.

Title: Exploring Suitable E3 Ligases for Targeted Protein Degradation Through Phenotypic-First Approach
Presenters: Kanae Gamo, Shinya Yokosaka, Shigeru Furukubo, Ryoma Hara, Michiko Watanabe, Tomoaki Hayashi, Yuichi Tateishi, Rumiko Ono, Kazuteru Aoki, Toshitake Kobayashi, Yusuke Tominari
Time and date: 12:00-14:00 (local time), Monday, May 20, 2024

This presentation will demonstrate the identification of degraders using novel E3 ligase by RaPPIDSTM platform technology with “Phenotypic-First Approach”, which enables highly efficient synthesis and evaluation of multiple degraders.
For more information: Centre for Targeted Protein Degradation events | University of Dundee, UK

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDSTM platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.

RaPPIDSTM (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDSTM platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media and Investor Contact:
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261

Back to news list

Return to TOP